Testing a radiation bead treatment for glioblastoma that has come back
Official title: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing whether a device that places tiny radiation beads into a brain tumor is safe for people whose glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary has returned.
Read our full plain-language summary
What the trial team says
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Key facts
- Registry number
- NCT05303467
- Stage of testing
- Phase 1
- Conditions studied
- Glioblastoma Multiforme, Recurrent Glioblastoma
Where it is running
This trial lists 9 sites.
-
Alabama
- University of Alabama Birmingham (Birmingham)
-
California
- University of California San Diego (San Diego)
- University of California San Francisco (San Francisco)
-
Florida
- Mayo Jacksonville (Jacksonville)
-
Illinois
- Northwestern Univerity (Chicago)
-
Maryland
- Johns Hopkins Interventional Radiology Center (Baltimore)
-
Missouri
- Washington University School of Medicine (St Louis)
-
New York
- Lenox Hill Hospital (New York)
-
Texas
- MD Anderson Cancer Center (Houston)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.